Suven Life Sciences Ltd has been granted two product patents, one each from the US and Japan, for its New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and were being developed as therapeutic agents. “They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia,’’ the Hyderabad-based company said in a release on Tuesday.